ES2011727A6 - Aqueous formulations of piperidinylcyclopentylheptenoic acid derivatives - Google Patents
Aqueous formulations of piperidinylcyclopentylheptenoic acid derivativesInfo
- Publication number
- ES2011727A6 ES2011727A6 ES8803876A ES8803876A ES2011727A6 ES 2011727 A6 ES2011727 A6 ES 2011727A6 ES 8803876 A ES8803876 A ES 8803876A ES 8803876 A ES8803876 A ES 8803876A ES 2011727 A6 ES2011727 A6 ES 2011727A6
- Authority
- ES
- Spain
- Prior art keywords
- aqueous formulations
- acid derivatives
- substituted
- acid
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000013011 aqueous formulation Substances 0.000 title abstract 2
- JAIYKLJZOBJGSG-UHFFFAOYSA-N 2-cyclopentyl-3-piperidin-1-ylhept-2-enoic acid Chemical class C1CCCC1C(C(O)=O)=C(CCCC)N1CCCCC1 JAIYKLJZOBJGSG-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- -1 PIPERIDINYL Chemical class 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 239000013020 final formulation Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
PROCEDIMIENTO PARA PREPARAR FORMULACIONES ACUOSAS QUECONTIENEN UN DERIVADO DE ACIDO PIPERIDINILCICLOPENTILHEPTENOICO. CONSISTE EN MEZCLAR EN AGUA ACIDO **FORMULA** (B)-7- 5-(1,1K-BIFENIL)-4-IL METOXI -3-HIDROXI-2-(1-PIPERIDINIL) CICLOPENTIL -4-HEPTENOICO, O SU SAL HIDROCLORURO, COMO INGREDIENTE ACTIVO, CON UNA CICLODEXTRINA SUSTITUIDA O NO SUSTITUIDA, O UN HIDRATO DE LA MISMA, TRAS LO CUAL SE AÑADEN LOS RESTANTES CONSTITUYENTES QUE EVENTUALMENTE FORMEN PARTE DE LA FORMULACION FINAL, QUE PUEDE PRESENTARSE EN FORMA DE JARABES, CAPSULAS Y PREPARADOS PARA INYECCION E INHALACION. EL PRODUCTO OBTENIDO ES UTIL PARA TRATAR O PREVENIR ENFERMEDADES CARDIOVASCULARES MEDIADAS POR TROMBOXANOPROCEDURE FOR PREPARING AQUEOUS FORMULATIONS CONTAINING A DERIVATIVE OF PIPERIDINYL CYCLOPENTILHEPTENOIC ACID. CONSISTS OF MIXING IN WATER ACID ** FORMULA ** (B) -7- 5- (1,1K-BIPHENYL) -4-IL METOXY -3-HYDROXY-2- (1-PIPERIDINIL) CYCLOPENTIL -4-HEPTENOICO, OR ITS HYDROCHLORIDE SALT, AS AN ACTIVE INGREDIENT, WITH A SUBSTITUTED OR NON-SUBSTITUTED CYCLODEXTRINE, OR A HYDRATE OF THE SAME, AFTER WHICH THE REMAINING CONSTITUENTS ARE ADDED THAT EVENTUALLY FORM PART OF THE FORMULATION AND FINAL FORMULATION, WHICH MAY BE PRESENTED PREPARED FOR INJECTION AND INHALATION. THE PRODUCT OBTAINED IS USEFUL TO TREAT OR PREVENT CARDIOVASCULAR DISEASES MEDIATED BY THROMBOXANE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB878729823A GB8729823D0 (en) | 1987-12-22 | 1987-12-22 | Complexes |
| GB888804422A GB8804422D0 (en) | 1988-02-25 | 1988-02-25 | Complexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2011727A6 true ES2011727A6 (en) | 1990-02-01 |
Family
ID=26293226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES8803876A Expired - Fee Related ES2011727A6 (en) | 1987-12-22 | 1988-12-21 | Aqueous formulations of piperidinylcyclopentylheptenoic acid derivatives |
Country Status (29)
| Country | Link |
|---|---|
| JP (1) | JPH02210A (en) |
| KR (1) | KR890009402A (en) |
| CN (1) | CN1034132A (en) |
| AT (1) | AT395943B (en) |
| AU (1) | AU615245B2 (en) |
| BE (1) | BE1001704A3 (en) |
| CA (1) | CA1328078C (en) |
| CH (1) | CH676665A5 (en) |
| DE (1) | DE3843059A1 (en) |
| DK (1) | DK712888A (en) |
| ES (1) | ES2011727A6 (en) |
| FI (1) | FI885920L (en) |
| FR (1) | FR2624731B1 (en) |
| GB (1) | GB2211737B (en) |
| GR (1) | GR880100854A (en) |
| HU (1) | HU204700B (en) |
| IE (1) | IE61995B1 (en) |
| IL (1) | IL88764A0 (en) |
| IT (1) | IT1224835B (en) |
| LU (1) | LU87411A1 (en) |
| MY (1) | MY103952A (en) |
| NL (1) | NL8803126A (en) |
| NO (1) | NO885689L (en) |
| NZ (1) | NZ227446A (en) |
| PH (1) | PH24982A (en) |
| PL (1) | PL276595A1 (en) |
| PT (1) | PT89301B (en) |
| SE (1) | SE502288C2 (en) |
| ZW (1) | ZW18088A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8814725D0 (en) * | 1988-06-21 | 1988-07-27 | Glaxo Group Ltd | Medicaments |
| AU616571B2 (en) * | 1988-10-28 | 1991-10-31 | Shiseido Company Ltd. | Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin |
| IT1269578B (en) * | 1994-04-22 | 1997-04-08 | Chiesi Farma Spa | MULTI-COMPONENT INCLUSION COMPLEXES WITH HIGH SOLUBILITY CONSISTING OF AN ACID TYPE DRUG, A CYCLODESTRINE AND A BASE. |
| KR100825736B1 (en) * | 2005-12-07 | 2008-04-29 | 한국전자통신연구원 | Apparatus for providing XML signnature in mobile environment and method thereof |
| KR100832740B1 (en) * | 2007-01-17 | 2008-05-27 | 한국과학기술원 | Mutant microorganism with improved branched chain amino acid production ability and method for producing branched chain amino acid using the same |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS503362B1 (en) * | 1970-06-10 | 1975-02-04 | ||
| JPS5443569B2 (en) * | 1972-07-05 | 1979-12-20 | ||
| HU181703B (en) * | 1980-05-09 | 1983-11-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents |
| JPS57183772A (en) * | 1981-04-29 | 1982-11-12 | Glaxo Group Ltd | Aminocyclopentanol acids and esters, manufacture and medicinal composition |
| JPS58116423A (en) * | 1981-12-28 | 1983-07-11 | Sumitomo Chem Co Ltd | Methanoprostacycline pharmaceutical composition |
| JPS58192821A (en) * | 1982-04-30 | 1983-11-10 | Dainippon Pharmaceut Co Ltd | Remedy for anoxia of cranial nerve cells |
| JPS5946228A (en) * | 1982-09-08 | 1984-03-15 | Zeria Shinyaku Kogyo Kk | Method for producing water-soluble and lymphatic drug of biologically active organic compound |
| JPS5973576A (en) * | 1982-09-16 | 1984-04-25 | グラクソ・グル−プ・リミテツド | Piperidinylcyclopentanolheptanoate |
| GB2127406B (en) * | 1982-09-16 | 1986-03-05 | Glaxo Group Ltd | Piperidinlycyclopentanolheptenoic acid salt |
| DE3346123A1 (en) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | PHARMACEUTICAL PREPARATIONS OF SUBSTANCES MEDICAL OR UNSTABLE IN WATER AND METHOD FOR THE PRODUCTION THEREOF |
| JPS60150039A (en) * | 1984-01-17 | 1985-08-07 | Minolta Camera Co Ltd | Amphibious fixed-focus camera |
| DE3504044A1 (en) * | 1985-02-04 | 1986-08-07 | Schering AG, Berlin und Bergkamen, 1000 Berlin | 9-HALOGEN PROSTAGLANDIN CLATHRATE AND THEIR USE AS A MEDICINAL PRODUCT |
| JPS6327440A (en) * | 1986-07-18 | 1988-02-05 | Sanraku Inc | Glucosylated branched cyclodextrin-containing composition |
-
1988
- 1988-12-21 GR GR880100854A patent/GR880100854A/en unknown
- 1988-12-21 IT IT8848702A patent/IT1224835B/en active
- 1988-12-21 FR FR8816902A patent/FR2624731B1/en not_active Expired - Fee Related
- 1988-12-21 IE IE382088A patent/IE61995B1/en not_active IP Right Cessation
- 1988-12-21 LU LU87411A patent/LU87411A1/en unknown
- 1988-12-21 NO NO88885689A patent/NO885689L/en unknown
- 1988-12-21 KR KR1019880017106A patent/KR890009402A/en not_active Ceased
- 1988-12-21 CH CH4758/88A patent/CH676665A5/de not_active IP Right Cessation
- 1988-12-21 JP JP63320759A patent/JPH02210A/en active Pending
- 1988-12-21 DK DK712888A patent/DK712888A/en not_active Application Discontinuation
- 1988-12-21 FI FI885920A patent/FI885920L/en not_active Application Discontinuation
- 1988-12-21 AT AT0313088A patent/AT395943B/en not_active IP Right Cessation
- 1988-12-21 PL PL27659588A patent/PL276595A1/en unknown
- 1988-12-21 BE BE8801423A patent/BE1001704A3/en not_active IP Right Cessation
- 1988-12-21 PH PH37963A patent/PH24982A/en unknown
- 1988-12-21 PT PT89301A patent/PT89301B/en not_active IP Right Cessation
- 1988-12-21 GB GB8829793A patent/GB2211737B/en not_active Expired - Fee Related
- 1988-12-21 NZ NZ227446A patent/NZ227446A/en unknown
- 1988-12-21 DE DE3843059A patent/DE3843059A1/en not_active Ceased
- 1988-12-21 SE SE8804607A patent/SE502288C2/en not_active IP Right Cessation
- 1988-12-21 CA CA000586606A patent/CA1328078C/en not_active Expired - Fee Related
- 1988-12-21 NL NL8803126A patent/NL8803126A/en not_active Application Discontinuation
- 1988-12-21 AU AU27356/88A patent/AU615245B2/en not_active Ceased
- 1988-12-21 CN CN88108916A patent/CN1034132A/en active Pending
- 1988-12-21 HU HU886537A patent/HU204700B/en not_active IP Right Cessation
- 1988-12-21 ZW ZW180/88A patent/ZW18088A1/en unknown
- 1988-12-21 ES ES8803876A patent/ES2011727A6/en not_active Expired - Fee Related
- 1988-12-22 MY MYPI88001508A patent/MY103952A/en unknown
- 1988-12-22 IL IL88764A patent/IL88764A0/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2087916T3 (en) | DERIVATIVE OF BICYCLIC PIRIMIDINE, METHOD TO PRODUCE THE SAME, AND PHARMACEUTICAL PREPARATION THAT CONTAINS THE SAME AS AN ACTIVE INGREDIENT. | |
| NO934501L (en) | Carboxylic acid derivatives, drugs containing these compounds, and process for their preparation | |
| FI810604L (en) | FOERFARANDE FOER FRAMSTAELLNING AV INDANDERIVAT | |
| ES2011727A6 (en) | Aqueous formulations of piperidinylcyclopentylheptenoic acid derivatives | |
| IT8025159A0 (en) | MEDICINAL PREPARATION WITH CYTOSTATIC ACTION, AS WELL AS DERIVATIVES OF ISOCYANURIC ACID AND PROCEDURE FOR THEIR PREPARATION. | |
| ES8701738A1 (en) | PROCEDURE FOR PREPARING NEW 1,2,4-TRIAZOLE-CARBAMATES | |
| ES427079A1 (en) | Phenothiazine derivatives, compositions thereof and methods of preparation thereof | |
| ES534550A0 (en) | PROCEDURE FOR THE MANUFACTURE OF PIRIMIDINE TRIAZOLE DERIVATIVES | |
| IE44030L (en) | Ó-amino-ketones. | |
| JPS56115793A (en) | Phosphonohydroxyacetic acid* its salt* their manufacture and drug thereof as active component | |
| ES2178626T3 (en) | PROCEDURE FOR THE PREPARATION OF 5-CARBOXIFTALIDA. | |
| DE2963010D1 (en) | 3-chloro-6-hydroxy-5-methylbenzoic acid derivatives, corresponding pharmaceutical preparations, growth promoting compositions, the use of the compounds for promoting growth in certain animals and their manufacture | |
| DE3884508D1 (en) | CYSTEIN DERIVATIVES WITH EXPECTORANS. | |
| MY101266A (en) | Pharmaceutical formulations | |
| ATE94766T1 (en) | PROCESS FOR THE PRODUCTION OF A GALENIC PREPARATION WITH OPTIMAL BIOAVAILABILITY OF THE ACTIVE SUBSTANCE 2-HYDROXY-5-METHYLAUROPHENONE OXIME (HMLO). | |
| DE2960927D1 (en) | N1-benzoyl-n2-phenyl-1,3-diaminopropane-2-ols and their salts, process for their preparation and medicaments containing them | |
| EP0019000A4 (en) | Osteoplastic promotor. | |
| DE69818060D1 (en) | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, THE PRODUCTION THEREOF, THE MEDICINAL PRODUCTS CONTAINING THEM | |
| GB936365A (en) | Chemotherapeutic methyl-sulphonyl-phenyl compounds | |
| IT1215340B (en) | IMMIDAZOL-1-IL-CARBOXYLIC ACID ESTER DERIVATIVES, PROCEDURES FOR THEIR PREPARATION AND FUNGICIDAL COMPOSITIONS THAT CONTAIN THE DERIVATIVE AS AN ACTIVE COMPONENT. | |
| FI57695C (en) | REFRIGERATION FOR INJECTION OF ENVIRONMENTAL 1-PHASE INJECTION SOLUTIONS WITH SULPHONAMIDES OR TRIMETOPRIM | |
| El Tahir et al. | Influence of chemotherapeutic agents on prostacyclin synthesis. II. Effects of tetracycline and penicillin G on prostacyclin synthesis by the rat thoracic aorta and myometrial tissues | |
| DE812912C (en) | Process for the preparation of a mixture of hexamethylene tetramine rhodanide and ammonium sulfate | |
| DE1815109A1 (en) | Bis- (N-tetracyclinomethyl-N-methyl-2-aminoaethyl) -aether | |
| GB936902A (en) | Quinazolinone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SA6 | Expiration date (snapshot 920101) |
Free format text: 2008-12-21 |
|
| FD1A | Patent lapsed |
Effective date: 20010402 |